Gennex Laboratories Ltd Stock Price Today (NSE: GENNEX)
Fundamental Score
Gennex Laboratories Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Gennex Laboratories Ltd share price today is ₹10.44, down 2.52% on NSE/BSE as of 17 June 2026. Gennex Laboratories Ltd (GENNEX) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹344.50 (Cr). The 52-week high for GENNEX share price is ₹17.25 and the 52-week low is ₹7.05. At a P/E ratio of 20.66x, GENNEX is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 10.23% and a debt-to-equity ratio of 0.41.
Gennex Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
Gennex Laboratories Ltd share price chart: 14.27% return over the past month. 52-week high ₹17.25, 52-week low ₹7.05.
Gennex Laboratories Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹11.32 | ₹11.45 | ₹11.01 | ₹11.24 | 1.65L (Cr) | |
| ₹11.86 | ₹11.89 | ₹11.18 | ₹11.25 | 8.97L (Cr) | |
| ₹11.78 | ₹12.10 | ₹11.60 | ₹11.77 | 3.35L (Cr) | |
| ₹12.02 | ₹12.39 | ₹11.60 | ₹11.77 | 6.19L (Cr) | |
| ₹12.60 | ₹12.75 | ₹12.05 | ₹12.11 | 14.32L (Cr) | |
| ₹12.68 | ₹12.99 | ₹12.11 | ₹12.67 | 29.78L (Cr) | |
| ₹11.24 | ₹12.50 | ₹11.24 | ₹12.27 | 41.14L (Cr) | |
| ₹10.99 | ₹11.95 | ₹10.56 | ₹11.04 | 8.43L (Cr) | |
| ₹10.98 | ₹11.40 | ₹10.61 | ₹10.95 | 15.16L (Cr) | |
| ₹9.36 | ₹10.95 | ₹9.09 | ₹10.95 | 50.88L (Cr) |
Gennex Laboratories Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹11.86 | ₹11.89 | ₹11.01 | ₹11.24 | -5.23% | |
| ₹10.24 | ₹12.99 | ₹8.78 | ₹11.77 | +14.94% | |
| ₹7.40 | ₹11.00 | ₹7.40 | ₹9.99 | +35.00% | |
| ₹10.36 | ₹11.46 | ₹7.05 | ₹7.13 | -31.18% | |
| ₹12.75 | ₹12.75 | ₹10.91 | ₹11.24 | -11.84% | |
| ₹14.14 | ₹14.89 | ₹11.66 | ₹12.30 | -13.01% | |
| ₹13.54 | ₹14.90 | ₹12.10 | ₹14.30 | +5.61% | |
| ₹16.56 | ₹16.70 | ₹13.40 | ₹13.48 | -18.60% | |
| ₹11.38 | ₹17.25 | ₹11.18 | ₹16.43 | +44.38% | |
| ₹12.39 | ₹13.25 | ₹10.84 | ₹11.18 | -9.77% | |
| ₹12.94 | ₹13.00 | ₹11.50 | ₹11.88 | -8.19% | |
| ₹12.33 | ₹15.19 | ₹12.20 | ₹12.75 | +3.41% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Gennex Laboratories Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Gennex Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of GENNEX across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Attractive Valuation (P/E: 20.66 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Consistent Growth Track Record (19.94% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (53.64% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (59.30% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Strong Interest Coverage (6.40x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Risk Factors
3 factors identified
Negative Free Cash Flow (₹-58.12 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Low Promoter Commitment (23.62%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Gennex Laboratories Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Gennex Laboratories Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Gennex Laboratories LtdGennex Laborato...Selected✓ GENNEX • 531739 | 29.4/100 | ₹10.44₹10 | ₹344.50₹344.50 | 20.66Average 20.7 Average | 10.23%Average 10.23% Average | 13.01%Average 13.01% Average | 0.41Excellent 0.4 Excellent | 59.30%Excellent 59.30% Excellent | 19.94%Excellent 19.94% Excellent | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Gennex Laboratories Ltd PE Ratio History
Historical price-to-earnings ratio for GENNEX — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹0.78 | ₹14.30 | 18.2x |
| FY 2024 | ₹0.61 | ₹16.33 | 26.9x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Gennex Laboratories Ltd Quarterly Performance
Latest quarterly metrics for GENNEX — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
11.56%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
4.14%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
19.94%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
59.30%
Compounded annual net profit growth over 5 years
Gennex Laboratories Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for GENNEX — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Gennex Laboratories Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Gennex Laboratories Ltd (GENNEX) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Gennex Laboratories Ltd
About GENNEX (Gennex Laboratories Ltd)
Gennex Laboratories Ltd is a pioneering pharmaceutical manufacturer committed to advancing global health through innovative solutions and unwavering quality. They specialize in the... complex synthesis and production of active pharmaceutical ingredients (APIs) and advanced intermediates, the essential building blocks for a wide range of medications. From their state-of-the-art facilities, Gennex orchestrates meticulous processes, adhering to the highest international standards of safety and efficacy. They stand at the forefront of pharmaceutical manufacturing, dedicating themselves to delivering crucial components that empower healthcare providers and improve patient outcomes worldwide. Gennex Laboratories Ltd thrives on a relentless pursuit of excellence and a dedication to addressing the evolving needs of the healthcare landscape. Their diverse portfolio encompasses a spectrum of therapeutic categories, focusing on providing high-quality ingredients for common ailments and specialized treatments alike. Gennex Laboratories Ltd skillfully crafts vital components used in cough and cold remedies, muscle relaxants, allergy relief medications, and treatments for urinary tract infections. They also produce crucial elements for medications combating fungal infections, depression, and mood disorders. This broad reach highlights Gennex's commitment to serving a wide array of patient needs and solidifies their role as a key supplier in the global pharmaceutical supply chain. With a focus on consistent quality and reliable supply, Gennex ensures that their partners can develop and deliver life-changing medications. Driven by a passion for scientific advancement and a commitment to ethical practices, Gennex Laboratories Ltd continuously invests in research and development to refine its processes and expand its product offerings. This dedication allows them to stay ahead of the curve, anticipating future healthcare needs and developing innovative solutions. Their team of expert scientists and engineers work collaboratively to optimize production techniques and ensure the consistent delivery of high-purity, high-quality ingredients. Gennex Laboratories Ltd strives to be a trusted partner in the pharmaceutical industry, working alongside leading companies to bring innovative and affordable medicines to patients around the globe.
Company Details
Key Leadership
Corporate Events
Latest News
GENNEX Share Price: Frequently Asked Questions
What is the current share price of Gennex Laboratories Ltd?
Gennex Laboratories Ltd (GENNEX) trades at ₹10.44 on NSE and BSE. Market cap ₹344.50 (Cr). Educational data only.
What is the P/E ratio of Gennex Laboratories Ltd?
Gennex Laboratories Ltd has a P/E of 20.66x vs industry average 31.77x.
What is the Bull Run score for Gennex Laboratories Ltd?
Gennex Laboratories Ltd has a Bull Run score of 29.4/100 based on 25+ financial parameters.
Does Gennex Laboratories Ltd pay dividends?
Gennex Laboratories Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Gennex Laboratories Ltd?
Gennex Laboratories Ltd has ROE of 10.23%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Gennex Laboratories Ltd?
Gennex Laboratories Ltd has debt-to-equity of 0.41.
Is Gennex Laboratories Ltd a good investment?
Bull Run gives Gennex Laboratories Ltd a score of 29.4/100. This is not investment advice — consult a SEBI-registered advisor.